http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2362132-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b98b7a4f2db57640340f944991d35f2c
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1804
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00
filingDate 2000-04-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4886b9b4c118804d1d7c302395fbb5ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd3fffc5c3cff5b141ec7acf2d1e88bb
publicationDate 2000-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2362132-A1
titleOfInvention Novel intermediate for the synthesis of prostaglandins
abstract An enantiomerically enriched compound of formula (1), wherein Ar is phenyl optionally substituted with one or more groups selected from haloalkyl, alkyl and halide. This compound can be isolated in crystalline form, and used in the preparation of (+)-16-[3-trifluoromethyl)phenoxyl-17,18,19,20-tetranor PGF2.alpha., isopropyl ester.
priorityDate 1999-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID246728
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419539363
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID158928092
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10929
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449964896
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394811
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535335
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419516083
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8051
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458394858

Total number of triples: 24.